ERBB2 and neoplasm: An only moderate agreement of surrogate tumor subtypes indicates the clinical value of biomarker re-testing on surgical specimens, and re-testing of at least HER2 and Ki67 should be considered to optimize tailored adjuvant therapy especially for patients treated with NAC.